Appropriateness of Beta-Lactam Allergy Record Updates After an Allergy Service Consult. (June 2020)

• Record Type: Journal Article
• Authors: Shaw, Bryan G.; Masic, Inela; Gorgi, Nancy; Kalfayan, Niree; Gilbert, Elise M.; Barr, Viktorija O.; Ison, Michael G.; McLaughlin, Milena M.
• Is Part Of: Journal of pharmacy practice. Volume 33:Number 3(2020:Jun.)
• Page Start: 243
• Page End: 246
• Publication Date: 2020-06
• Subjects: allergy -- antimicrobial stewardship -- beta-lactam -- antibiotics -- allergy service consult; Pharmacy -- Periodicals; Pharmacology -- Periodicals; 615.1
• DOI: 10.1177/0897190018797767
• Languages: English
• ISSNs: 0897-1900

Abstract

Background: Many patients with a self-reported penicillin allergy go on to tolerate beta-lactam antibiotics. Allergy specialists may be consulted to determine the nature and extent of the allergy. However, electronic allergy records must be appropriately updated such that recommendations are carried forward. Objective: To determine the percentage of patients who have their electronic allergy record updated after an allergy service consult (ASC). Methods: This was a retrospective study of patients with at least 1 documented beta-lactam allergy and had an ASC during (inpatient) or prior to (outpatient) hospital admission at Northwestern Memorial Hospital and Prentice Women's Hospital in Chicago, Illinois. Results: Within the study period, a total of 26 526 patients were identified as having a documented antibiotic allergy, with 21 657 patients (81.6% of patients with allergies) having a listed beta-lactam allergy. Of these patients, 1689 (7.8%) patients were identified as having an ASC during or prior to admission, with 598 patients meeting inclusion criteria. Changes in the allergy record were recommended by the ASC for 62% (n = 371) of patients; however, the allergy record was updated after the ASC in 74.9% (n = 278) of patients. Conclusion: ASC recommendations to delabel a patient as beta-lactam allergic must result in updating the allergy record in order to optimize future treatment. Given the low proportion of allergy-labeled patients tested, programs outside formal ASCs should be considered.